Minerva Neurosciences (NERV) Receives CRL from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Visit StreetInsider.com at http://www.streetinsider.com/Trading+Halts/Minerva+Neurosciences+%28NERV%29+Receives+CRL+from+FDA+for+New+Drug+Application+for+Roluperidone+for+the+Treatment+of+Negative+Symptoms+in+Patients+with+Schizophrenia/22837781.html for the full story.